Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
Moderna dosed the first participant in a Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy, for patients with advanced or metastatic solid tumors. The candidate encodes for seven antigens and is administered alongside checkpoint inhibitor therapy to evaluate safety, tolerability, and dose escalation.
Key figures
- Drug Name
- mRNA-4200
- Phase Of Trial
- Phase 1
- Antigen count
- 7
- Clinical trial id
- NCT06880549
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.